ASCO Gastrointestinal Cancer Symposium | Conference

Patients with recurrent hepatocellular carcinoma after liver transplantation were treated with lenvatinib and saw promising efficacy.

The CheckMate 9X8 trial did not hit the primary end point of progression-free survival superiority with nivolumab plus standard of care vs standard of care alone in metastatic colorectal cancer.

The observational GALAXY study found that use of a ctDNA assay could help determine which patients with colorectal cancer stand to benefit the most by receipt of adjuvant chemotherapy.

Treatment with trastuzumab deruxtecan produced promising efficacy results for patients with HER2-positive metastatic colorectal cancer.

Results from a phase 1/2 study showed that a combination of encorafenib, cetuximab, and nivolumab was well tolerated and yielded promising responses in patients with microsatellite stable BRAFV600E metastatic colorectal cancer.

Although the combination of regorafenib and pembrolizumab failed to meet significance for progression-free survival, an improvement in overall survival and disease control were observed for patients with microsatellite stable colorectal cancer.

Pembrolizumab, binimetinib , and bevacizumab led to deep and durable responses for patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer.

Patients with KRAS-mutant metastatic colorectal cancer who were treated with a combination containing onvansertib had a tolerable safety profile.

Patients with advanced hepatocellular carcinoma achieved notable improvements in survival and responses following treatment with transarterial chemoembolization and lenvatinib.

Interim results of a phase 2 trial found a safe toxicity profile for olaparib plus pembrolizumab in advanced cholangiocarcinoma.